AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.13 |
Market Cap | 3.73M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.87 |
PE Ratio (ttm) | -0.4 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.16 |
Volume | 12,959 |
Avg. Volume (20D) | 34,370 |
Open | 1.14 |
Previous Close | 1.13 |
Day's Range | 1.13 - 1.18 |
52-Week Range | 0.91 - 1.75 |
Beta | undefined |
About ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and ...
Analyst Forecast
According to 3 analyst ratings, the average rating for ARTL stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 419.48% from the latest price.
3 years ago · newsfilecorp.com
Artelo Biosciences to Present at the Q4 Investor Summit on November 17thSolana Beach, California--(Newsfile Corp. - November 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signa...